Seladelpar’s Efficacy for PBC Demonstrated in a Real-World Clinical Setting The efficacy of seladelpar as a second-line therapy in patients with PBC has been demonstrated in a real-world clinical setting.

The efficacy of #Seladelpar as a second-line therapy in patients with primary biliary cholangitis (#PBC) has been demonstrated in a real-world clinical setting.

Read more: https://bit.ly/4pRad1g

#RareDisease #PrimaryBiliaryCholangitis

#livdelzi for #PBC efficacy highlights
✅ 62% met primary endpoint vs. unprecedented 20% placebo
🔥 25% normalized alkphos vs. 0% placebo
🔥 improvement in objective itch scales likely makes #seladelpar itch beneficial vs. itch neutral
#livertwitter...

#seladelpar is now #livdelzi as it gains ⁦@US_FDA⁩ approval as second line therapy for #PBC
More great news for people living with this disease ⁦@PBCers⁩ ⁦@pbcercarol⁩ #livertwitter ...